Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (July 2025)
31 slides from Syngene International's investor presentation, Jul 24, 2025

Slide 1: Regulation 30 filing cover letter
Ref: Syn/CS/SE/IP/2025-26/Jul/11 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com July 24, 2025 To,

Slide 2: Investor Presentation July 2025
Investor Presentation July 2025

Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements

Slide 4: Contents
Contents 1 Q1 FY26 Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Putting Science to Work 3

Slide 5: Q1 FY26 Highlights
1 Q1 FY26 Highlights Syngene

Slide 6: Q1 FY26 performance
Q1 FY26 performance Operating Highlights Q1 FY26 Financial Highlights • Syngene successfully completed a USFDA Good Clinical Practices (GCP) Revenue from Operations Operating EBITDA margin inspection of its Human Pharmacology Unit with no observations Rs 875 Cr ( 11% Y-o-Y) 23.6% (21.5% in Q1 FY25)

Slide 7: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work

Slide 8: Partner in innovation: Who we are and what we do
Partner in innovation: #Putting Science to Work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more than Established track record in solutions across pharmaceuticals, b

Slide 9: Our journey so far
Our journey so far 2019 – 2025 Globalization and strategic collaboration Continued investments and growth • Expanded collaboration with BMS, Amgen and • Expanded into formulations development Zoetis • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expansion of Integrated Drug Disc

Slide 10: Key facts and figures
Key facts and figures ~400 14 out of top 20 400+ World class infrastructure active clients pharma companies are patents International presence with global clients held with clients campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standa

Slide 11: Syngene – one of the largest integrated CRDMO players in India
Syngene – one of the largest integrated CRDMO players in India One-stop platform for integrated drug discovery, development and manufacturing across modalities Expanding capacity Building capabilities for future Building partnerships (in Million sq. ft.) (#) (#) 2.5+ 8,235 ~400 0.9 3,526 250+ March’

Slide 12: 3-pronged growth strategy across diversified platform
3-pronged growth strategy across diversified platform Research Services (CRO) Large Molecule CDMO Small Molecule CDMO Discovery Services Dedicated R&D Centers Clinical Development Flexible Platform with capability Ring-fenced infrastructure for Comprehensive research services Process development Dru

Slide 13: Our Strategy
Our Strategy Research Services Development and Development and Manufacturing Services – Manufacturing Services – Provide an integrated end-to-end Large Molecules Small Molecules therapeutic discovery services Encompassing drug discovery, pre- Utilize existing Chemistry, Manufacturing, Implement a co

Slide 14: Syngene strengths
3 Syngene strengths Syngene

Slide 15: Syngene strengths
Syngene strengths A global scale CRDMO player Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track

Slide 16: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers 8,235 Inspiring technical excellence and providing opportunities to grow total headcount • Thrive 360: A holistic approach to employee well being addressing physical, mental and emotional, social, financial and professional health through targ

Slide 17: State-of-the-art infrastructure and new capabilities with global presence
Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs… USA based Biologics facility HQ campus at Bangalore, India Fully functional Bayview, Baltimore, 90 Acres (3,64,217 sq. mt) where most of R&D Centre at USA Syngene’s capabilities

Slide 18: Range of successful collaboration models
5 We currently operate a range of successful collaboration models Dedicated R&D Labs Full time equivalent (FTE) Fee For service (FFS) Risk / Reward Model Outcome – based model with Service Level Agreement • Customers receive ring-fenced • A dedicated team of scientific • Services are provided • A mi

Slide 19: Experience across industry segments and global partners
Our experience spans multiple industry segments and partners us with global leaders across the world… Large & Mid-Sized Emerging Chemicals/ BioPharma BioPharma (EBP) Animal Health AgroChem CPG Polymers Note : This is a representative selection of the customers Syngene works with. We work with ~ 400

Slide 20: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations driven by Focused execution through strong Project certified operational leaders Management Six Sigma Black Belt certified staff in each Structured program management for executing client service line and

Slide 21: Syngene digital initiatives driving innovation and operational excellence
Syngene digital initiatives aimed at driving innovation and operational At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve Certification as per ISO 13485:2016, ISO/IEC scientific and enterprise functions. 27001

Slide 22: Committed to safety and sustainability
Committed to safety and sustainability Committed to environmental protection Safety is our first priority • Committed to Science-based targets for greenhouse gases • Accredited with ISO 45001:2018 for Occupational • 95% of total hazardous and non-hazardous Health and Safety (OH&S) waste recycled mea

Slide 23: Accreditations
Accreditations • USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities. • GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory • GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Ass

Slide 24: Industry recognition for scientific capability and business excellence
We have consistently received industry recognition for our scientific capability and business excellence • CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma • EcoVadis Sustainability Rating, 2024 : Syngene secured silver rating in the EcoVadis sustainability index for

Slide 25: Robust risk management framework
Robust risk management framework Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance. Risk Management Board of Directors Risk Owner Executive Committee Committee (BOD) • Continuou

Slide 26: Financials
4 Financials

Slide 27: Q1FY26 financial highlights
Q1FY26 financial highlights All figures in Rs. Mn unless otherwise specified Balance Sheet Highlights Particulars Q1FY26 Q1 FY25 YoY change Q4 FY25 QoQ change Revenue from operations 8,745 7,897 11% 10,180 -14% As on 30th June 2025 All figures in Rs. Mn unless otherwise specified Other income 177 1

Slide 28: Shareholding and Share Information
5 Shareholding and Share Information

Slide 29: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.

Slide 30: Shareholding and Share Information
Shareholding and Share Information Syngene’s shareholders* Syngene’s Share Information* NSE Ticker SYNGENE 1% BSE Ticker 539268 Promoter & Promoter Group Market Cap (Rs. Mn) 2,57,438 47% 53% Public % free-float^ 47% ESOP Trust Free-float market cap (Rs. Mn) 1,21,810 Share Outstanding (Mn) 403 • As o

Slide 31: For more details
For more details Visit our website www.syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Nandini Agarwal / Shubham Jain Shotorupa Ghosh +91 7838382527 / +91 6377651994 +91 8450977080 inve
Source: NSE filing, Jul 24, 2025
More decks from Syngene International Ltd.
Q2 FY27 Earnings Presentation13 slides · Oct 28, 2026
Q2 FY27 Earnings Presentation32 slides · Oct 27, 2026
Q1 FY27 Earnings Presentation12 slides · Jul 30, 2026
Q1 FY27 Earnings Presentation32 slides · Jul 29, 2026
Q1 FY27 Earnings Presentation31 slides · July 2026
Q4 FY26 Earnings Presentation32 slides · Apr 30, 2026